Advertisement

Relationship of systemic pentraxin-3 values with coronary plaque components on optical coherence tomography and post-percutaneous coronary intervention outcomes in patients with stable angina pectoris

      Highlights

      • The clinical significance of pentraxin-3 (PTX3) values in stable angina pectoris (SAP) patients remains undetermined.
      • We assessed the impact of PTX3 values on coronary plaques and post-percutaneous coronary intervention (PCI) outcomes.
      • Peak post-PCI PTX3 values was related to thin-cap fibroatheroma (TCFA) and post-PCI irregular protrusion.
      • Peak post-PCI PTX3 was an independent predictor of major adverse cardiac events (MACE) after PCI in SAP patients.

      Abstract

      Background and aims

      Elevated pentraxin-3 (PTX3) values are associated with vulnerable plaque existence and poor outcomes in acute coronary syndrome patients. The clinical significance of PTX3 values in stable angina pectoris (SAP) patients is, however, undetermined. We investigated the relationship of systemic PTX3 values and coronary plaque components and post-percutaneous coronary intervention (PCI) outcomes in SAP patients.

      Methods

      We included 93 consecutive de-novo lesions in 93 SAP patients with a normal pre-PCI high-sensitivity cardiac troponin-T (<0.014 ng/mL), undergoing pre- and post-PCI optical coherence tomography (OCT). Systemic PTX3 values were obtained immediately pre- and post-PCI, at 24-h and 9-month post-PCI.

      Results

      Peak post-PCI PTX3 values correlated with thinnest fibrous cap thickness (r = −0.23, p = 0.03) and lipid length (r = 0.24, p = 0.03), and were higher in patients with lesions having OCT-derived thin-cap fibroatheroma (6.67 (3.19–7.33) vs. 3.13 (2.34–4.11) ng/mL, p = 0.04) and post-stenting irregular tissue protrusion (4.76 (3.31–6.80) vs. 2.98 (2.23–4.06) ng/mL, p = 0.003) than in those without. At 9-month follow-up, cardiac event-free survival was poorer in patients with a peak post-PCI PTX3 value ≥ 4.08 ng/mL (upper tertile) (log-rank test χ2 = 9.0; p = 0.003). Multivariate Cox regression analysis showed a peak post-PCI PTX3 value ≥ 4.08 ng/mL as an independent predictor of MACE (hazard ratio, 3.915; 95% CI, 1.129–13.583; p = 0.03).

      Conclusions

      Peak post-PCI PTX3 values correlated with pre-PCI plaque characteristics and post-PCI outcomes, providing a good prognostic factor of outcomes in SAP patients undergoing elective PCI.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Libby P.
        Inflammation in atherosclerosis.
        Arterioscler. Thromb. Vasc. Biol. 2012; 32: 2045-2051
        • Libby P.
        • Ridker P.M.
        • Maseri A.
        Inflammation and atherosclerosis.
        Circulation. 2002; : 1135-1143
        • Sano T.
        • Tanaka A.
        • Namba M.
        • Nishibori Y.
        • Nishida Y.
        • et al.
        C-reactive protein and lesion morphology in patients with acute myocardial infarction.
        Circulation. 2003; 108: 282-285
        • Introna M.
        • Alles V.V.
        • Castellano M.
        • Picardi G.
        • De Gioia L.
        • et al.
        Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites.
        Blood. 1996; 87: 1862-1872
        • Garlanda C.
        • Bottazzi B.
        • Bastone A.
        • Mantovani A.
        Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility.
        Annu. Rev. Immunol. 2005; 23: 337-366
        • Razvina O.
        • Jiang S.
        • Matsubara K.
        • Ohashi R.
        • Hasegawa G.
        • et al.
        Differential expression of pentraxin 3 in neutrophils.
        Exp. Mol. Pathol. 2015; 98: 33-40
        • Casula M.
        • Montecucco F.
        • Bonaventura A.
        • Liberale L.
        • Vecchié A.
        • et al.
        Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases.
        Vasc. Pharmacol. 2017; 99: 1-12
        • Savchenko A.
        • Imamura M.
        • Ohashi R.
        • Jiang S.
        • Kawasaki T.
        • et al.
        Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions.
        J. Pathol. 2008; 215: 48-55
        • Matsuura Y.
        • Hatakeyama K.
        • Imamura T.
        • Tsuruda T.
        • Shibata Y.
        • et al.
        Different distribution of pentraxin 3 and C-reactive protein in coronary atherosclerotic plaques.
        J. Atheroscler. Thromb. 2012; 19: 837-845
        • Latini R.
        • Maggioni A.P.
        • Peri G.
        • Gonzini L.
        • Lucci D.
        • et al.
        Lipid Assessment Trial Italian Network (Latin) Investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction.
        Circulation. 2004; 110: 2349-2354
        • Inoue K.
        • Sugiyama A.
        • Reid P.C.
        • Ito Y.
        • Miyauchi K.
        • et al.
        Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris.
        Arterioscler. Thromb. Vasc. Biol. 2007; 27: 161-167
        • Tearney G.J.
        • Yabushita H.
        • Houser S.L.
        • Aretz H.T.
        • Jang I.K.
        • et al.
        Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography.
        Circulation. 2003; 107: 113-119
        • Jang I.K.
        • Tearney G.J.
        • MacNeill B.
        • Takano M.
        • Moselewski F.
        • et al.
        In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography.
        Circulation. 2005; 111: 1551-1555
        • Jia H.
        • Abtahian F.
        • Aguirre A.D.
        • Lee S.
        • Chia S.
        • et al.
        In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography.
        J. Am. Coll. Cardiol. 2013; 62: 1748-1758
        • TIMI Study Group
        The thrombolysis in myocardial infarction (TIMI) trial.
        N. Engl. J. Med. 1985; 312: 932-936
        • Gibson C.M.
        • Cannon C.P.
        • Daley W.L.
        • Dodge Jr., J.T.
        • Alexander Jr., B.
        • et al.
        TIMI frame count: a quantitative method of assessing coronary artery flow.
        Circulation. 1996; 3: 879-888
        • Lee T.
        • Yonetsu T.
        • Koura K.
        • Hishikari K.
        • Murai T.
        • et al.
        Impact of coronary plaque morphology assessed by optical coherence tomography on cardiac troponin elevation in patients with elective stent implantation.
        Circ. Cardiovasc. Interv. 2011; 4: 378-386
        • Yabushita H.
        • Bouma B.E.
        • Houser S.L.
        • Aretz H.T.
        • Jang I.K.
        • et al.
        Characterization of human atherosclerosis by optical coherence tomography.
        Circulation. 2002; 106: 1640-1645
        • Tearney G.J.
        • Regar E.
        • Akasaka T.
        • Adriaenssens T.
        • Barlis P.
        • et al.
        International working group for intravascular optical coherence tomography (IWG-IVOCT). Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the international working group for intravascular optical coherence tomography standardization and validation.
        J. Am. Coll. Cardiol. 2012; 59: 1058-1072
        • Kume T.
        • Okura H.
        • Kawamoto T.
        • Yamada R.
        • Miyamoto Y.
        • et al.
        Assessment of the coronary calcification by optical coherence tomography.
        EuroIntervention. 2011; 6: 768-772
        • Soeda T.
        • Uemura S.
        • Park S.J.
        • Jang Y.
        • Lee S.
        • et al.
        Incidence and clinical significance of poststent optical coherence tomography findings: one-year follow-up study from a multicenter registry.
        Circulation. 2015; 132: 1020-1029
        • Gonzalo N.
        • Serruys P.W.
        • Okamura T.
        • Shen Z.J.
        • Onuma Y.
        • et al.
        Optical coherence tomography assessment of the acute effects of stent implantation on the vessel wall: a systematic quantitative approach.
        Heart. 2009; 95: 1913-1919
        • Kume T.
        • Akasaka T.
        • Kawamoto T.
        • Ogasawara Y.
        • Watanabe N.
        • et al.
        Assessment of coronary arterial thrombus by optical coherence tomography.
        Am. J. Cardiol. 2006; 97: 1713-1717
        • Kotooka N.
        • Inoue T.
        • Fujimatsu D.
        • Morooka T.
        • Hashimoto S.
        • et al.
        Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening.
        Atherosclerosis. 2008; 197: 368-374
        • Kornowski R.
        • Hong M.K.
        • Tio F.O.
        • Bramwell O.
        • Wu H.
        • et al.
        In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia.
        J. Am. Coll. Cardiol. 1998; 31: 224-230
        • Cusack M.R.
        • Marber M.S.
        • Lambiase P.D.
        • Bucknall C.A.
        • Redwood S.R.
        Systemic inflammation in unstable angina is the result of myocardia necrosis.
        J. Am. Coll. Cardiol. 2002; 39: 1917-1923
        • Guo R.
        • Li Y.
        • Wen J.
        • Li W.
        • Xu Y.
        Elevated plasma level of pentraxin-3 predicts in-hospital and 30-day clinical outcomes in patients with non-ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention.
        Cardiology. 2014; 129: 178-188
        • Vavik V.
        • Pedersen E.K.R.
        • Svingen G.F.T.
        • Tell G.S.
        • Schartum-Hansen H.
        • et al.
        Usefulness of higher levels of cardiac troponin T in patients with stable Angina pectoris to predict risk of acute myocardial infarction.
        Am. J. Cardiol. 2018; 122: 1142-1147
        • Kimura S.
        • Inagaki H.
        • Haraguchi G.
        • Sugiyama T.
        • Miyazaki T.
        • et al.
        Relationships of elevated systemic pentraxin-3 levels with high-risk coronary plaque components and impaired myocardial perfusion after percutaneous coronary intervention in patients with ST-elevation acute myocardial infarction.
        Circ. J. 2014; 78: 159-169
        • Salio M.
        • Chimenti S.
        • De Angelis N.
        • Molla F.
        • Maina V.
        • et al.
        Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction.
        Circulation. 2008; 117: 1055-1064
        • Norata G.D.
        • Marchesi P.
        • Pulakazhi Venu V.K.
        • Pasqualini F.
        • Anselmo A.
        • et al.
        Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis.
        Circulation. 2009; 120: 699-708
        • Koga S.
        • Ikeda S.
        • Yoshida T.
        • Nakata T.
        • Takeno M.
        • et al.
        Elevated levels of systemic pentraxin 3 are associated with thin-cap fibroatheroma in coronary culprit lesions: assessment by optical coherence tomography and intravascular ultrasound.
        JACC Cardiovasc. Interv. 2013; 6: 945-954
        • Karakas M.F.
        • Buyukkaya E.
        • Kurt M.
        • Motor S.
        • Akcay A.B.
        • Buyukkaya S.
        • et al.
        Serum pentraxin 3 levels are associated with the complexity and severity of coronary artery disease in patients with stable angina pectoris.
        J. Investig. Med. 2013; 61: 278-285
        • Bryniarski K.L.
        • Tahk S.J.
        • Choi S.Y.
        • Soeda T.
        • Higuma T.
        • Yamamoto E.
        • et al.
        Clinical, angiographic, IVUS, and OCT predictors for irregular protrusion after coronary stenting.
        EuroIntervention. 2017; 12: e2204-e2211
        • Bernelli C.
        • Shimamura K.
        • Komukai K.
        • Capodanno D.
        • Saia F.
        • Garbo R.
        • et al.
        Impact of culprit plaque and atherothrombotic components on incomplete stent apposition in patients with ST-elevation myocardial infarction treated with everolimus-eluting stents - an OCTAVIA substudy.
        Circ. J. 2016; 80: 895-905
        • Lee R.
        • Ahn H.R.
        • Shin M.H.
        • Kim H.N.
        • Lee Y.H.
        • et al.
        Association of plasma pentraxin-3 level with lipid levels and cardiovascular risk factors in people with No history of lipid-lowering medication: the dong-gu study.
        J. Atheroscler. Thromb. 2019; 26: 738-745
        • Ishino M.
        • Shishido T.
        • Suzuki S.
        • Katoh S.
        • Sasaki T.
        • Funayama A.
        • et al.
        Deficiency of long pentraxin PTX3 promoted neointimal hyperplasia after vascular injury.
        J. Atheroscler. Thromb. 2015; 22: 372-378